There is a definite pattern of strong
institutional accumulation with IDBE. This is very positive
over the medium and long term. In the short term
Market Makers may feel the need to shake-out some of the
more loosely held shares. They have not been doing
this very actively just yet IMHO. Just a few baby
shakes. It seems they are taking a leisurely approach to
their accumulation for the moment.
This is not
the case at SCLN (which is on the very edge of an
explosive price movement). Several Market Makers have
pulled out all the stops to get as many shares of SCLN
as possible. For example, yesterday they droped the
price over $2.50 in the twinkling of an eye and on no
volume. It was truley shameless. They hit all the stop
sells and paniced the newbies and weak hands. They
scored big time: to the tune of several 100K shares.
Funnily enough, after 2 solid days of pounding, they
still can't drop SCLN below the 9 day moving average!
The stock is just that strong. Really unbelievable.
If it is not on you watchlist, it should be. By the
way, there is a great article in IBD this morning on
Sciclone, so heads up.
Anyway, back on the topic of
IDBE, this is a great stock. It could move up sharply
in the immediate future, but it wouldn't surprise me
if it stalled for a while just under $10 U.S. That's
frequently a tough hurdle to get over, and it might take a
Who dares, wins!
Vancouver company launches new superbug test
A new test for detecting methicillin-resistant
Staphylococcus aureus (MRSA) has been launched by Vancouver's
I.D. Biomedical Corporation. The company's Velogene
Rapid MRSA Identification Assay diagnostic test has
already received approval from the US Food and Drug
Administration, and approval from Health Canada was expected by
the end of August. Marketing to hospitals across
North America and Europe began this summer. The test
costs $10 � about the same as current hospital tests �
and the company hopes to sell about 5 million
Company president Dr. Tony Holler says the
test, which takes about 2 hours to complete, is the
first truly rapid test to identify MRSA; normally it
takes up to 2 days to get test results. About 4.6
million tests for MRSA are carried out annually in US
hospital laboratories. "For hospitals, it's a huge
problem," says Holler, who estimates that the market is
growing by about 10% a year. If hospitals "can save 1 day
through early diagnosis and treatment, that saves $1000
plus. The speed means that you are treating patients
with the right antibiotic quicker, which leads to
shorter hospital stays."
The test identifies the
gene responsible for methicillin antibiotic resistance
approximately 90 minutes after a primary culture is obtained.
The company says the test is both fast and accurate.
In clinical trials at 4 US hospitals, the test
demonstrated 100% accuracy when compared with polymerase chain
reaction, the current gold standard in gene-identification
I.D. Biomedical is now preparing for
clinical trials for a second diagnostic test to detect
vancomycin-resistant enterococci bacteria. � � Heather Kent, Vancouver
IDB is expected to receive a royalty of about US$2
per test. Its' platform, from which its' MRSA test is
derived, has a market worth approximately US$500
Oops, maybe it has something to do with my
personal gender identity problems, but I have really
believed that April is female.
Sorry for that
April!! The first dance is reserved for you
Mr. or Mrs. loosing money?
Check out Sir Holler's Web Site on IDBE and learn
why we are all here. It will answer many of your
questions. He is not an analyst, just an investor, so take
the information with that in mind. Here's the
See you all next week!